» Articles » PMID: 32319604

HER4 Promotes the Progression of Colorectal Cancer by Promoting Epithelial‑mesenchymal Transition

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2020 Apr 23
PMID 32319604
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) remains one of the most common cancer types worldwide. A few previous studies have examined whether HER4 may promote the progression of CRC. The present study examined the associations among the expression levels of members of the HER family, and investigated the potential mechanism underlying the function of HER4 in CRC cells. Immunohistochemistry analysis was conducted to detect the expression levels of HER family members in patients with CRC. HER4 expression was knocked down using short hairpin RNA in HCT116 cells, and confirmed by quantitative PCR and western blotting. The proliferation and adhesion of CRC cells were analyzed by CCK‑8 assays and adhesive assays, respectively. Flow cytometry was used to measure cell apoptosis. Western blotting and immunofluorescence staining in CRC cells were performed to identify proteins related to epithelial‑mesenchymal transition. The proportion of patients with CRC presenting positive expression of the HER family members epidermal growth factor receptor (EGFR), HER2, HER3 and HER4 were 72.1, 45.2, 43.8 and 34.2%, respectively. No relationship was found between HER4 and EGFR, HER2 or HER3 expression. Higher expression of HER4 was positively associated with lymph node metastasis (P=0.039). In the present study, HER4 expression was found to be associated with an unfavorable clinical outcome in patients with CRC (Plogrank=0.020). Cell proliferation was inhibited, and apoptosis was increased following HER4 knockdown. Furthermore, HER4 knockdown increased the expression of E‑cadherin and decreased the expressions of N‑cadherin and vimentin (P<0.05). HER4 expression was found to be unrelated to other HER family members. In the present study, positive expression of HER4 promoted the progression of CRC through epithelial‑mesenchymal transition.

Citing Articles

Integrative analysis of causal associations between neurodegenerative diseases and colorectal cancer.

Wang F, Chen L, Nie M, Li Z Heliyon. 2024; 10(15):e35432.

PMID: 39170445 PMC: 11336615. DOI: 10.1016/j.heliyon.2024.e35432.


The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases.

High P, Guernsey C, Subramanian S, Jacob J, Carmon K Pharmaceutics. 2024; 16(7).

PMID: 39065587 PMC: 11279420. DOI: 10.3390/pharmaceutics16070890.


Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling.

Albadari N, Xie Y, Li W Front Pharmacol. 2024; 14:1340401.

PMID: 38269272 PMC: 10806212. DOI: 10.3389/fphar.2023.1340401.


Performance of the Use of Genetic Information to Assess the Risk of Colorectal Cancer in the Basque Population.

Garcia-Etxebarria K, Etxart A, Barrero M, Nafria B, Segues Merino N, Romero-Garmendia I Cancers (Basel). 2022; 14(17).

PMID: 36077729 PMC: 9454881. DOI: 10.3390/cancers14174193.


Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer.

Chen D, Ye Y, Guo S, Yao K Front Mol Biosci. 2022; 8:800945.

PMID: 35004854 PMC: 8735837. DOI: 10.3389/fmolb.2021.800945.


References
1.
Lo H . Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets. 2010; 10(8):840-8. PMC: 3615246. DOI: 10.2174/156800910793357970. View

2.
Baiocchi G, Lopes A, Coudry R, Rossi B, Soares F, Aguiar S . ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis. 2009; 24(9):1059-68. DOI: 10.1007/s00384-009-0702-6. View

3.
Guo Y, Duan Z, Jia Y, Ren C, Lv J, Guo P . HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer. Oncol Lett. 2018; 15(5):6629-6635. PMC: 5876439. DOI: 10.3892/ol.2018.8124. View

4.
Shi J, Li F, Yao X, Mou T, Xu Z, Han Z . The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. Oncogene. 2018; 37(22):3022-3038. PMC: 5978807. DOI: 10.1038/s41388-018-0204-5. View

5.
Roskoski Jr R . The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2013; 79:34-74. DOI: 10.1016/j.phrs.2013.11.002. View